Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Psoriatic Arthritis

Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Michele B. Kaufman, PharmD, BCGP  |  December 25, 2015

In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…

New SLE Drug May Allow Patients to Reduce Steroid Use

Michele B. Kaufman, PharmD, BCGP  |  December 16, 2015

In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…

One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis

Reuters Staff  |  November 30, 2015

NEW YORK (Reuters Health)—Apremilast is effective in patients with difficult to treat psoriasis of the scalp and nails, according to long-term results of two phase 3 trials. Investigators had previously reported 16-week data from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2 trials. The new report includes…

Bariatric Surgery Tied to Improvement in Psoriasis, Psoriatic Arthritis

Megan Brooks  |  November 11, 2015

NEW YORK (Reuters Health)—Obese patients with psoriasis or psoriatic arthritis are apt to experience significant symptomatic relief following bariatric surgery, according to a new chart review. Specifically, the study found that more than half of the patients with psoriasis or psoriatic arthritis reported improvements in their disease following surgery. Dr. Soumya Reddy, assistant professor of…

Evidence Lacking for Tests for Psoriasis Patients Using Biologic Agents

Will Boggs, MD  |  July 25, 2015

NEW YORK (Reuters Health)—Various organizations recommend dozens of screening and monitoring tests for patients with psoriasis or psoriatic arthritis who are using systemic biologic agents, despite sparse evidence to support any of them. “At a population level, these medications have proven to be very safe and the evidence does not support such extensive and frequent…

Secukinumab Effective for Treating Psoriatic Arthritis

Reuters Staff  |  July 15, 2015

NEW YORK (Reuters Health)—The anti-interleukin-17A monoclonal antibody secukinumab improves signs and symptoms in patients with psoriatic arthritis, according to results from Novartis’ FUTURE 2 trial. In earlier studies, secukinumab has demonstrated superior effectiveness to placebo and etanercept in improving the signs and symptoms of psoriasis. Dr. Iain B. McInnes from the University of Glasgow in…

Many Psoriasis Patients Have Undiagnosed Arthritis

Kathryn Doyle  |  June 23, 2015

(Reuters Health)—Up to 15% of people with psoriasis have undiagnosed arthritis that’s related to the skin condition, according to a new review. “The important takeaway,” said Dr. Abby Van Voorhees, director of the Psoriasis and Phototherapy Treatment Center at the Hospital of the University of Pennsylvania in Philadelphia, “would be that further education is needed…

Biosimilars for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  June 17, 2015

Biosimilars for etanercept and sarilumab are being examined in multiple Phase 3 trials for their effects in RA and psoriasis patients.

Ixekizumab Clinical Trials Continue; FDA Updates Warning Label for Varenicline

Michele B. Kaufman, PharmD, CGP, RPh  |  June 15, 2015

It seems to have begun in Norway, the international pressure to switch patients from well-known brand biologic agents, such as Remicade (infliximab), to biosimilar agents, due to a significant cost advantage.1 This biosimilar came with a 39% price markdown last year compared with the brand, and when Norway called for bids, the discount went to…

Clinical Trials Ongoing for Brodalumab

Michele B. Kaufman, PharmD, BCGP  |  June 5, 2015

Brodalumab, an interleukin (IL) 17 inhibitor, is currently in early clinical trials (Phase 1b and Phase 2) for a number of different autoimmune diseases.1 Amgen recently terminated its co-development and commercialization agreement with AstraZeneca for the brodalumab investigational program in trials for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. Amgen’s decision to…

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences